

RECEIVED

JUN 06 2003



TECH CENTER 1600/2900

1600

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003

TIME: 10:53:06

Input Set : A:\015270-005913US.APP

Output Set: N:\CRF4\05302003\I724953.raw

3 <110> APPLICANT: Schenk, Dale B.  
 4 Elan Pharmaceuticals  
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Diseases  
 8 <130> FILE REFERENCE: 015270-005913US  
 10 <140> CURRENT APPLICATION NUMBER: US 09/724,953  
 11 <141> CURRENT FILING DATE: 2000-11-28  
 13 <150> PRIOR APPLICATION NUMBER: US 09/585,817  
 14 <151> PRIOR FILING DATE: 2000-06-01  
 16 <150> PRIOR APPLICATION NUMBER: US 60/137,010  
 17 <151> PRIOR FILING DATE: 1999-06-01  
 19 <160> NUMBER OF SEQ ID NOS: 34  
 21 <170> SOFTWARE: PatentIn Ver. 2.1  
 23 <210> SEQ ID NO: 1  
 24 <211> LENGTH: 13  
 25 <212> TYPE: PRT  
 26 <213> ORGANISM: Artificial Sequence  
 28 <220> FEATURE:  
 29 <223> OTHER INFORMATION: Description of Artificial Sequence:influenza  
 30 hemagglutinin HA 307-319 universal T-cell epitope  
 32 <400> SEQUENCE: 1  
 33 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr  
 34 1 5 10  
 37 <210> SEQ ID NO: 2  
 38 <211> LENGTH: 13  
 39 <212> TYPE: PRT  
 40 <213> ORGANISM: Artificial Sequence  
 42 <220> FEATURE:  
 43 <223> OTHER INFORMATION: Description of Artificial Sequence:PADRE universal  
 44 T-cell epitope  
 46 <220> FEATURE:  
 47 <221> NAME/KEY: MOD\_RES  
 48 <222> LOCATION: (3)  
 49 <223> OTHER INFORMATION: Xaa = any amino acid  
 51 <400> SEQUENCE: 2  
 W--> 52 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala  
 53 1 5 10  
 56 <210> SEQ ID NO: 3  
 57 <211> LENGTH: 16  
 58 <212> TYPE: PRT  
 59 <213> ORGANISM: Artificial Sequence  
 61 <220> FEATURE:  
 62 <223> OTHER INFORMATION: Description of Artificial Sequence:malaria CS T3  
 63 epitope universal T-cell epitope

P. 6  
ENTERED

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003

TIME: 10:53:06

Input Set : A:\015270-005913US.APP  
Output Set: N:\CRF4\05302003\I724953.raw

65 <400> SEQUENCE: 3  
66 Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val  
67 1 5 10 15  
70 <210> SEQ ID NO: 4  
71 <211> LENGTH: 10  
72 <212> TYPE: PRT  
73 <213> ORGANISM: Artificial Sequence  
75 <220> FEATURE:  
76 <223> OTHER INFORMATION: Description of Artificial Sequence:Hepatitis B  
77 surface antigen HBsAg 19-28 universal T-cell  
78 epitope  
80 <400> SEQUENCE: 4  
81 Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile  
82 1 5 10  
85 <210> SEQ ID NO: 5  
86 <211> LENGTH: 19  
87 <212> TYPE: PRT  
88 <213> ORGANISM: Artificial Sequence  
90 <220> FEATURE:  
91 <223> OTHER INFORMATION: Description of Artificial Sequence:heat shock  
92 protein 65 hsp65 153-171 universal T-cell epitope  
94 <400> SEQUENCE: 5  
95 Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly  
96 1 5 10 15  
98 Asn Glu Gly  
102 <210> SEQ ID NO: 6  
103 <211> LENGTH: 14  
104 <212> TYPE: PRT  
105 <213> ORGANISM: Artificial Sequence  
107 <220> FEATURE:  
108 <223> OTHER INFORMATION: Description of Artificial Sequence:bacillus  
109 Calmette-Guerin universal T-cell epitope  
111 <400> SEQUENCE: 6  
112 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu  
113 1 5 10  
116 <210> SEQ ID NO: 7  
117 <211> LENGTH: 15  
118 <212> TYPE: PRT  
119 <213> ORGANISM: Artificial Sequence  
121 <220> FEATURE:  
122 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid  
123 TT 830-844 universal T-cell epitope  
125 <400> SEQUENCE: 7  
126 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu  
127 1 5 10 15  
130 <210> SEQ ID NO: 8  
131 <211> LENGTH: 21  
132 <212> TYPE: PRT  
133 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING DATE: 05/30/2003  
PATENT APPLICATION: US/09/724,953 TIME: 10:53:06

Input Set : A:\015270-005913US.APP  
Output Set: N:\CRF4\05302003\I724953.raw

135 <220> FEATURE:  
136 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid  
137 TT 947-967 universal T-cell epitope  
139 <400> SEQUENCE: 8  
140 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser  
141 1 5 10 15  
143 Ala Ser His Leu Glu  
144 20  
147 <210> SEQ ID NO: 9  
148 <211> LENGTH: 16  
149 <212> TYPE: PRT  
150 <213> ORGANISM: Artificial Sequence  
152 <220> FEATURE:  
153 <223> OTHER INFORMATION: Description of Artificial Sequence:HIV gp120 T1  
154 universal T-cell epitope  
156 <400> SEQUENCE: 9  
157 Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala  
158 1 5 10 15  
161 <210> SEQ ID NO: 10  
162 <211> LENGTH: 22  
163 <212> TYPE: PRT  
164 <213> ORGANISM: Artificial Sequence  
166 <220> FEATURE:  
167 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90549 (Abeta  
168 1-7/tetanus toxoid 830-844 in a MAP4  
169 configuration)  
171 <400> SEQUENCE: 10  
172 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe  
173 1 5 10 15  
175 Ile Gly Ile Thr Glu Leu  
176 20  
179 <210> SEQ ID NO: 11  
180 <211> LENGTH: 28  
181 <212> TYPE: PRT  
182 <213> ORGANISM: Artificial Sequence  
184 <220> FEATURE:  
185 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90550 (Abeta  
186 1-7/tetanus toxoid 947-967 in a MAP4  
187 configuration)  
189 <400> SEQUENCE: 11  
190 Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp  
191 1 5 10 15  
193 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu  
194 20 25  
197 <210> SEQ ID NO: 12  
198 <211> LENGTH: 43  
199 <212> TYPE: PRT  
200 <213> ORGANISM: Artificial Sequence  
202 <220> FEATURE:

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003  
TIME: 10:53:06

Input Set : A:\015270-005913US.APP  
Output Set: N:\CRF4\05302003\I724953.raw

203 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90542 (Abeta  
204 1-7/tetanus toxoid 830-844 + 947-967 in a linear  
205 configuration)  
207 <400> SEQUENCE: 12  
208 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe  
209 1 5 10 15  
211 Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu  
212 20 25 30  
214 Arg Val Pro Lys Val Ser Ala Ser His Leu Glu  
215 35 40  
218 <210> SEQ ID NO: 13  
219 <211> LENGTH: 22  
220 <212> TYPE: PRT  
221 <213> ORGANISM: Artificial Sequence  
223 <220> FEATURE:  
224 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90576 (Abeta  
225 3-9/tetanus toxoid 830-844 in a MAP4  
226 configuration)  
228 <400> SEQUENCE: 13  
229 Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe  
230 1 5 10 15  
232 Ile Gly Ile Thr Glu Leu  
233 20  
236 <210> SEQ ID NO: 14  
237 <211> LENGTH: 20  
238 <212> TYPE: PRT  
239 <213> ORGANISM: Artificial Sequence  
241 <220> FEATURE:  
242 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90562 (Abeta  
243 1-7/peptide on linear conformation)  
245 <220> FEATURE:  
246 <221> NAME/KEY: MOD\_RES  
247 <222> LOCATION: (3)  
248 <223> OTHER INFORMATION: Xaa = any amino acid  
250 <400> SEQUENCE: 14  
W--> 251 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu  
252 1 5 10 15  
254 Phe Arg His Asp  
255 20  
258 <210> SEQ ID NO: 15  
259 <211> LENGTH: 34  
260 <212> TYPE: PRT  
261 <213> ORGANISM: Artificial Sequence  
263 <220> FEATURE:  
264 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90543 (Abeta  
265 1-7 X 3/peptide in linear conformation)  
267 <220> FEATURE:  
268 <221> NAME/KEY: MOD\_RES  
269 <222> LOCATION: (24)

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003  
TIME: 10:53:06

Input Set : A:\015270-005913US.APP  
Output Set: N:\CRF4\05302003\I724953.raw

270 <223> OTHER INFORMATION: Xaa = any amino acid  
272 <400> SEQUENCE: 15  
273 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala  
274 1 5 10 15  
W--> 276 Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala  
277 20 25 30  
279 Ala Ala  
283 <210> SEQ ID NO: 16  
284 <211> LENGTH: 34  
285 <212> TYPE: PRT  
286 <213> ORGANISM: Artificial Sequence  
288 <220> FEATURE:  
289 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein  
290 with Abeta immunogenic epitope  
292 <220> FEATURE:  
293 <221> NAME/KEY: MOD\_RES  
294 <222> LOCATION: (3)  
295 <223> OTHER INFORMATION: Xaa = any amino acid  
297 <400> SEQUENCE: 16  
W--> 298 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu  
299 1 5 10 15  
301 Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg  
302 20 25 30  
304 His Asp  
308 <210> SEQ ID NO: 17  
309 <211> LENGTH: 20  
310 <212> TYPE: PRT  
311 <213> ORGANISM: Artificial Sequence  
313 <220> FEATURE:  
314 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein  
315 with Abeta immunogenic epitope  
317 <220> FEATURE:  
318 <221> NAME/KEY: MOD\_RES  
319 <222> LOCATION: (10)  
320 <223> OTHER INFORMATION: Xaa = any amino acid  
322 <400> SEQUENCE: 17  
W--> 323 Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu  
324 1 5 10 15  
326 Lys Ala Ala Ala  
327 20  
330 <210> SEQ ID NO: 18  
331 <211> LENGTH: 24  
332 <212> TYPE: PRT  
333 <213> ORGANISM: Artificial Sequence  
335 <220> FEATURE:  
336 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein  
337 with Abeta immunogenic epitope  
339 <400> SEQUENCE: 18  
340 Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/724,953

DATE: 05/30/2003  
TIME: 10:53:07

Input Set : A:\015270-005913US.APP  
Output Set: N:\CRF4\05302003\I724953.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 3  
Seq#:14; Xaa Pos. 3  
Seq#:15; Xaa Pos. 24  
Seq#:16; Xaa Pos. 8  
Seq#:17; Xaa Pos. 10  
Seq#:32; Xaa Pos. 2  
Seq#:33; Xaa Pos. 1